Prescription opioid volume declined 17% in 2018, which is the largest single-year drop ever recorded, according to IQVIA's annual "Medicine Use and Spending in the U.S." report.
The Association for Accessible Medicines said the Food and Drug Administration's guidance on naming biological products delays the development of biosimilars.
Those recognized this week were chosen by a panel of judges from more than 15,000 customer-submitted entries in the annual program, which was conducted last October for American Pharmacists month.